Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Acquired by Xponance Inc.

Xponance Inc. grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 22,456 shares of the biopharmaceutical company’s stock after acquiring an additional 1,806 shares during the quarter. Xponance Inc.’s holdings in Alnylam Pharmaceuticals were worth $5,284,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Allworth Financial LP boosted its holdings in Alnylam Pharmaceuticals by 6.8% in the fourth quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after acquiring an additional 38 shares in the last quarter. Nixon Peabody Trust Co. boosted its holdings in Alnylam Pharmaceuticals by 1.9% in the fourth quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after acquiring an additional 43 shares in the last quarter. Huntington National Bank boosted its holdings in Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 45 shares in the last quarter. IFP Advisors Inc boosted its holdings in Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 47 shares in the last quarter. Finally, Nwam LLC raised its stake in shares of Alnylam Pharmaceuticals by 5.8% in the fourth quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company’s stock worth $213,000 after purchasing an additional 50 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ALNY. Needham & Company LLC restated a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. Morgan Stanley raised their price objective on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Sanford C. Bernstein reduced their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. StockNews.com upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Finally, Chardan Capital restated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have issued a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $304.26.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $253.44 on Thursday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The business’s 50 day moving average price is $255.99 and its 200-day moving average price is $259.55. The firm has a market capitalization of $32.81 billion, a PE ratio of -116.79 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.21, for a total transaction of $169,204.23. Following the transaction, the executive vice president now owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Phillip A. Sharp sold 11,250 shares of the business’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 71,234 shares of company stock valued at $19,958,097. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.